Your first 90 days
Your first 90 days on Galafold for Fabry disease
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Galafold is approved only for certain changes in the GLA gene, so the first step is a genetic result checked against the label's list. Galafold has no REMS, no vaccine requirement and no lab test the label requires before the first fill. Insurers want the variant documented, and a specialty pharmacy ships the capsules to your home. This page lays out the first 3 months from the FDA label, the Amicus Assist program and one insurer's written rules.
What has to happen before the first bottle ships
Galafold has no REMS, so the first fill waits on a genetic result on the label's amenable list, an insurance approval and a pharmacy delivery. These are the 7 things in the way, in order.
A genetic test that names your GLA variant
Galafold is approved only for an amenable GLA variant, so the exact variant has to be known.
- Amicus says a genetic test from saliva or blood finds the variant, and that it is required to diagnose Fabry disease in females.Fabry testing
The amenability check
The label lists the amenable variants in a table, based on a lab test in cells.
- Your doctor checks your variant against that table before prescribing.
- A variant missing from the table is either not amenable or has not been tested.FDA label
Whether the variant causes Fabry disease
Being on the list does not prove a variant causes the disease.
- The label says a clinical genetics professional should judge it as causing Fabry disease.
- It strongly recommends genetics advice when the variant is of uncertain significance or may be harmless.FDA label
A kidney function check
The label says Galafold is cleared from the body mainly by the kidneys.
- It does not recommend it when eGFR is below 30 or for people on dialysis.
- No dose change is needed when eGFR is 30 or higher.FDA label
A list of everything you take, including caffeine
The label says caffeine lowers Galafold levels and may make it work less well.
- The Patient Information asks you to tell your doctor about medicines or supplements that contain caffeine, along with all other medicines.FDA label
Pregnancy and breastfeeding, raised before day 1
The label says only 3 pregnant women took Galafold in trials, too few to judge the risk.
- It is not known whether Galafold passes into breast milk.
- A pregnancy and breastfeeding study collects data, and joining is voluntary.FDA label
The referral form and your consent
The office faxes or emails the Galafold Referral Form, which also serves as the prescription in some states.
- You sign a consent form to enroll in Amicus Assist, and a separate signature enrolls you in copay help.Referral Form
The days that matter
Counted from the first dose, with the every-other-day pattern, the 4-hour fast around each capsule and the 28-day refills the wallet pack sets. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.The variant is checked against the label
Your doctor confirms the GLA variant is in the label's amenable table and judged to cause Fabry disease.
- Insurers such as Cigna want that genetic result documented in the request.
Referral form, consent and the insurance request
The office sends the Galafold Referral Form to Amicus Assist with copies of your insurance cards.
- You sign the consent page that enrolls you in the program.
A Case Manager calls
Amicus says a Case Manager contacts your doctor's office and you within 1 business day.
- The office learns whether prior authorization is needed, and you learn when a Welcome Kit will arrive.
The specialty pharmacy ships
After any prior authorization is confirmed, the specialty pharmacy coordinates delivery.
- Amicus says the capsules are shipped directly to your door.
First capsule, then a 4-hour fast window
One 123mg capsule, swallowed whole, at a time of day you can keep.
- No food or caffeine for 2 hours before and after.
- The Instructions for Use say to write the start date on the blister card.
A day off, marked on the card
No capsule is due on the second day.
- The Instructions for Use say to press out a white cardboard circle on off days, so the card shows which day comes next.
Second capsule, same time as day 1
Doses fall on days 1, 3, 5 and so on.
- A missed dose can be taken within 12 hours of the usual time.
- After 12 hours, skip it and keep the original schedule.
New wallet pack, then about every 28 days
Each card holds 14 capsules for 28 days, with the last capsule on day 27.
- Amicus says your Case Manager can help with the refill process and home delivery.
New wallet pack, number 2
New wallet pack, number 3
Three months in
The label sets no blood or urine test schedule for Galafold.
- In the main trial, the kidney biopsy measure behind the approval was taken at 6 months.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Galafold label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated August 28, 2025, read from the FDA's label database today. FDA label
- August 2025
The current DailyMed version took effect on August 28th, with no new prescribing text. Its wording matches the March 2025 label, and the outer carton panel carries the August date.March 2025 label
- March 2025
The FDA approved adding angioedema, a swelling under the skin, to the side effects reported after approval. The FDA approval letter for that change is dated March 19th.FDA letter S-009
- June 2024
The FDA approved adding new amenable GLA variants to the label's table on June 5th.FDA letter S-008
- June 2023
On June 20th the FDA approved adding caffeine to the fasting rule and naming which drinks are allowed. On the same day it approved one new amenable variant for the table.FDA letter S-006, S-007
- December 2021
The FDA approved 2 new amenable GLA variants for the label's table on December 10th.FDA letter S-005
- August 2018
The FDA granted accelerated approval on August 10th based on lower GL-3 in kidney cells. It required a confirmatory trial and a pregnancy and breastfeeding study.FDA approval letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- One capsule, every other day
The label dose is 123mg by mouth once every other day, at the same time of day.
- It is never taken on 2 days in a row, and the label has one strength and no dose steps.FDA label
- An empty stomach, a 4-hour fast
No food and no caffeine for at least 2 hours before and 2 hours after each capsule.
- In a label study, a meal 1 hour before or after a dose lowered Galafold levels by 37% to 42%.FDA label
- What you can drink during the fast
The label allows water, whether plain, flavored or sweetened, during the fast.
- Fruit juice without pulp and caffeine-free carbonated drinks are allowed too, but nothing that contains caffeine.FDA label
- Swallow it whole
The capsule is swallowed whole and never cut, crushed or chewed.
- Amicus suggests pressing the capsule out of the card at an angle so it is not crushed.Taking Galafold
- If you miss a dose
The label says a missed dose can be taken if no more than 12 hours have passed since the usual time.
- After 12 hours, it is not made up, and the next dose is taken on the next planned day.FDA label
- Caffeine in medicines and supplements
In a label study, 190mg of caffeine taken with a dose cut Galafold levels by 55%.
- The Patient Information asks you to tell your doctor about any medicine or supplement that contains caffeine.FDA label
- Kidney function
The label does not recommend Galafold for eGFR below 30 or for dialysis.
- With severe kidney impairment, Galafold levels were about 4.3 times higher in a single-dose study.FDA label
- Storage
Room temperature, 68 to 77 degrees Fahrenheit (20 to 25 Celsius).
- Keep the capsules in the blister card to protect them from moisture, and out of the reach of children.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
The most common side effects
In the 6-month placebo-controlled trial, headache occurred in 35% on Galafold against 21% on placebo.
- Stuffy or runny nose with sore throat, urinary tract infection, nausea and fever were also among the most common.FDA label
Swelling under the skin
Angioedema, a swelling under the skin, was added to the label in March 2025 from reports after approval.
- The label does not say how often it happens.
- The Patient Information says to call your doctor about side effects.FDA letter S-009
What the label does not list
Galafold has no boxed warning and no warnings section, so the label names no emergency symptoms of its own.
- Side effects can be reported to Amicus at 1-877-426-4287 or the FDA at 1-800-FDA-1088.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedCigna's policy wants a pathogenic or likely pathogenic amenable variant, documented, and a geneticist, nephrologist or Fabry specialist. The Amicus Assist Case Manager tells the office whether prior authorization is needed and what the steps are.Cigna policy
- The variant is of uncertain significanceCigna's February 2026 update removed an earlier path that accepted a variant of uncertain significance with Fabry symptoms. The label strongly recommends a clinical genetics professional review such variants before treatment.Cigna policy
- The variant is not in the label's tableThe label says an unlisted variant is either not amenable or has not been tested. It points doctors to Amicus Medical Information at 1-877-4AMICUS for more information.FDA label
- You also receive enzyme replacement infusionsCigna does not cover Galafold used together with Fabrazyme or Elfabrio. Cigna notes Galafold is not FDA approved for use with enzyme replacement, and the prescriber decides which treatment continues.Cigna policy
- A refill asked for too earlySome plans cap how many capsules can be dispensed at one time. The Blue Cross Blue Shield Federal Employee Program allows 42 capsules per 84 days, which equals 3 wallet packs.FEP Blue policy
- A copay you cannot payWith commercial insurance, the copay program offers as little as $0 a month, subject to program maximums. People with Medicare, Medicaid, TRICARE, VA, DOD or other government coverage are excluded. The Amicus Patient Assistance Program gives free drug to uninsured or underinsured people who qualify.Amicus Assist on Galafold.com
Cigna prior authorization policy, February 15, 2026
- Age 18 or older
- A pathogenic or likely pathogenic amenable GLA variant based on in vitro assay data, with documentation
- Prescribed by, or in consultation with, a geneticist, a nephrologist or a doctor who specializes in Fabry disease
- Not used together with Fabrazyme or Elfabrio
Approval length. A year at a time.
This policy took effect on February 15, 2026 and cites the March 2025 label, whose prescribing text matches the current DailyMed version. Other plans set their own rules, and the Blue Cross Blue Shield Federal Employee Program is one example. It asks for an amenable variant without the pathogenic wording and allows 42 capsules per 84 days. It is here as an example of what a plan asks for, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A Case Manager who verifies and explains coverage, helps with prior authorization questions, and coordinates prescription deliveries and refills
- A Patient Education Liaison who answers questions about Fabry disease and Galafold and helps set a routine, without giving medical advice
- Copay help for commercial insurance, as little as $0 a month subject to program maximums, not valid with Medicare, Medicaid, TRICARE, VA, DOD or state drug programs
- The Amicus Patient Assistance Program, free product for eligible uninsured or underinsured patients
- Help finding independent charitable foundations, which set their own rules
- Spanish-speaking Case Managers
Details as the drugmaker publishes them. Amicus Assist Fabry support
Five questions for the pharmacist or the support line
- Which specialty pharmacy will ship my Galafold, and what number will it call from?
- Do any of my medicines or supplements contain caffeine?
- Does my plan limit how many wallet packs I can get at once?
- When should I order my next pack so I never run out?
- If I miss a dose, how do I count the 12 hours?
Questions people ask in the first weeks
How do I know if my Fabry variant is amenable to Galafold?
Your doctor checks your GLA variant against Table 2 of the FDA label, which lists the amenable variants. Amicus also runs an online search tool for doctors licensed in the US. The label says a clinical genetics professional should judge whether the variant causes Fabry disease.
Can I drink coffee or tea on Galafold?
Not within 2 hours before or 2 hours after a dose. The label says caffeine lowers Galafold levels and may make it work less well. Water, juice without pulp and caffeine-free carbonated drinks are allowed during the fast.
What if I miss a dose of Galafold?
The label says to take it if no more than 12 hours have passed since the usual time. After 12 hours, skip it and take the next dose on the next planned day. The label says Galafold is never taken on 2 days in a row.
Can I take Galafold with kidney disease?
The label says no dose change is needed when eGFR is 30 or higher. It does not recommend Galafold when eGFR is below 30 or for people on dialysis. Galafold has not been studied in Fabry patients with eGFR below 30.
How long does one pack of Galafold last?
Each wallet pack holds 14 capsules, which last 28 days at one capsule every other day. The Galafold MyDay app can send refill reminders, according to Amicus.
Can I take Galafold with Fabrazyme or another enzyme infusion?
The label does not cover combining them, and Cigna says Galafold is not FDA approved for use with enzyme replacement. Cigna's policy does not cover Galafold together with Fabrazyme or Elfabrio. Any decision about combining or switching treatments belongs to the prescriber.
Does Medicare cover Galafold?
The Amicus pages reviewed here do not describe Medicare coverage of Galafold. The Amicus copay program excludes Medicare and other government insurance by its terms. Amicus Assist can help identify independent foundations, and its Patient Assistance Program gives free product to those who qualify.
Free email alert
Hear when the Galafold label changes
One email the day the FDA revises the Galafold label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Galafold only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Fabry disease for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - GALAFOLD- migalastat hydrochloride capsule (prescribing information, Patient Information and Instructions for Use, SPL version 18), Amicus Therapeutics US, via DailyMed, August 28, 2025.
- GALAFOLD prescribing information, revised 3/2025 (Drugs@FDA file 208623s009lbl.pdf), FDA, Drugs@FDA, March 19, 2025.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, November 7, 2026.
- NDA 208623 replacement approval letter, Galafold (migalastat) capsules, 123 mg, effective August 10, 2018, FDA, August 10, 2018.
- NDA 208623/S-005 supplement approval letter, Galafold (migalastat) capsules, FDA, December 10, 2021.
- NDA 208623/S-006 and S-007 supplement approval letter, Galafold (migalastat) capsules, FDA, June 20, 2023.
- NDA 208623/S-008 supplement approval letter, Galafold (migalastat) capsules, FDA, June 5, 2024.
- NDA 208623/S-009 supplement approval letter, Galafold (migalastat) capsules, FDA, March 19, 2025.
- Amicus Assist | Galafold (migalastat) | Official Patient Site, Amicus Therapeutics, November 7, 2026.
- Fabry Support - Amicus Assist Patient, Amicus Therapeutics, November 7, 2026.
- Patient Support - Fabry Support (hcp-fabry-support) - Amicus Assist HCP, Amicus Therapeutics, November 7, 2026.
- Galafold (migalastat) Referral Form, Amicus Therapeutics, November 7, 2026.
- Taking Galafold | Galafold (migalastat) | Official Patient Site, Amicus Therapeutics, November 7, 2026.
- Testing | Galafold (migalastat) | Official Patient Site, Amicus Therapeutics, November 7, 2026.
- Galafold® (migalastat) Amenability | Search Amenable GLA Variants, Amicus Therapeutics, November 7, 2026.
- Support for Galafold® (migalastat) Patients with AMICUS ASSIST®, Amicus Therapeutics, November 7, 2026.
- Fabry Disease – Galafold, Drug Coverage Policy IP0400, Cigna, February 15, 2026.
- Pharmacy Policy 5.30.057, Galafold, Blue Cross Blue Shield Federal Employee Program, April 1, 2026.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing geneticist. Found an error? Use the report link in the footer and it will be checked against the source.